• The American Congress of Obstetricians and Gynecologists estimates that 14%-23% of pregnant women experience depressive symptoms during pregnancy. Although both untreated depressive symptoms and antidepressant exposure are associated with poor maternal and newborn outcomes, trends for antidepressant medication use during pregnancy have increased.
What is already known about this subject
• Since antidepressant treatment guidelines recommend at least 6-9 months of antidepressant medication use for patients with major depression, medication adherence plays a key role to help patients achieve desired outcomes. However, more than 40% of patients discontinue treatment during the first 3-4 months, which may result in worse health and economic outcomes.
• Women with low socioeconomic status are at high risk to develop depression. Few studies report antenatal antidepressant medication use behavior in low-income pregnant women.
• Nearly 80% of depressed pregnant women were prescribed selective serotonin reuptake inhibitors, and 20% used more than 1 antidepressant during the antenatal period.
• The estimated median time to discontinuation of antidepressant medication use during pregnancy was 80 days.
• Of 804 pregnant women, 45% showed treatment nonpersistence to antidepressant medication therapy.
• Racial disparity in antidepressant treatment nonpersistence was identified in low-income pregnant women.
a primary diagnosis of major depression and who initiated antidepressant use during the 280 days preceding the delivery date. The major depression was identified by International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes (296.2, 296.3, 300.4, or 311). The subject's index date was defined as the date of a patient's first pharmacy claim for an antidepressant medication after the estimated date of conception. Those who received antidepressants during 6 months prior to the index date were excluded. To measure persistence, we included women who had at least 2 antidepressant prescription claims during the pregnancy. Additionally, to be eligible for our study, the pregnant women needed to show continuous Medicaid enrollment for at least 1 year before and 1 year after the estimated date of conception. Women with a diagnosis for schizophrenia or bipolar disorders or those with any antipsychotic medication claim during the eligibility period were excluded from the study. Antidepressant medications were identified from pharmacy claims. If a woman had more than 1 maternal delivery during the study period, the first delivery meeting eligibility criteria was included for analysis. Our main outcome measure was antidepressant medication treatment nonpersistence during pregnancy. Based on literature review and clinical perspectives, pharmacotherapy treatment discontinuation was defined as the presence of a 15-day gap in therapy. 25, 31 Antidepressant medication treatment nonpersistence was defined as having a gap between 2 consecutive prescriptions of at least 15 days during the 180 days after the index date or from the index date to maternal delivery date, whichever occurred first.
Antidepressant medication use patterns during pregnancy among eligible pregnant women were measured, including type of antidepressant used, total number of antidepressants used, and trimester of antidepressant initiation. Potential predictors, including demographics (age, race); history of antidepressant use and depression diagnosis during the 1 year before pregnancy; comorbidity; and medical utilization, including all-cause physician office visits, hospitalization, and emergency department (ED) visits during 1 year before pregnancy were used to estimate the risk for antenatal antidepressant therapy nonpersistence. The Charlson Comorbidity Index, weighted score (ranging 1-6), was used as a proxy for severity of comorbidity. ICD-9-CM codes were used to identify comorbid conditions from Medicaid claims data. 32 Descriptive statistics summarized the study population's characteristics and antidepressant use patterns. Antidepressant nonpersistence was reported by Kaplan-Meier plots for the time to discontinuation of antidepressant treatment during pregnancy. We employed a proportional hazards model to identify significant predictors associated with risk for antidepressant therapy nonpersistence during pregnancy. The level of statistical significance was set a priori at P < 0.05. All analyses were performed using SAS 9.2 (SAS Institute, Cary, NC).
hypertension of the newborn, and shows equivocal findings for outcomes related to fetal growth and gestation. 6, 14 Although controversy exists regarding antidepressant use during pregnancy, trends for antidepressant medication use to treat antenatal depression continue to increase. [15] [16] [17] [18] A recent meta-analysis found that antidepressant medication use during pregnancy significantly increases risks for low birth weight and preterm birth. 19 Yet, there is higher risk for depression recurrence when antidepressant medication maintenance therapy is not used during pregnancy, 20, 21 with 1 study reporting recurrence 5 times more likely in women who discontinue antidepressant therapy during the antenatal period than in those who maintain antidepressant treatments. 22 In adults with major depressive episodes, The American Psychiatric Association recommends continuous antidepressant pharmacotherapy lasting at least 6-9 months. 23 Antidepressant medication use persistence becomes an important factor when managing antenatal depression. Evidence shows that more than 40% of patients discontinue their medications during the first 3-4 months. Discontinuing antidepressant medication treatment shows an association with poor clinical outcomes. [24] [25] [26] [27] [28] Although antidepressant medication use for depressive episodes can positively affect behavioral, clinical, and health outcomes among various populations, few studies report antidepressant medication use in pregnancy, particularly in low-income populations. For instance, it is not clear whether pregnant women with depression actually receive appropriate pharmacotherapy, whether antidepressant medication use behavior changes during antepartum, or how frequently women discontinue antidepressant therapy when pregnant.
Moreover, low socioeconomic status is significantly associated with the occurrence of depression. Individuals with less than a high school education, work disability, unemployment, or without health insurance coverage tend to be more severely depressed. 3, 29, 30 Understanding antidepressant use behavior in low-income pregnant women could help identify barriers to managing antenatal depression and help develop effective and safe antidepressant treatment parameters for disadvantaged populations. Our objective was to examine antidepressant medication use behavior in low-income pregnant women by using South Carolina Medicaid administrative claims data. The purpose of this study was to assess antidepressant pharmacotherapy treatment persistence during pregnancy and identify patient characteristics predictive of antidepressant medication treatment persistence.
■■ Methods
This retrospective cohort study used South Carolina Medicaid claims data (2004) (2005) (2006) (2007) (2008) (2009) ). First, we identified pregnant women aged 18 years and older with single or multiparous live births during the study period. Then, we calculated the date of conception as 280 days prior to the maternal delivery date. Next, we restricted our analysis to pregnant women who had Table 1 presents the descriptive characteristics of the study population. More than 80% of the eligible women were white, with an average age of 26 years when giving birth. During the 1 year before pregnancy, nearly 40% of women used antidepressants; less than 20% had a diagnosis of depression; one-third showed at least 1 ED visit; and 15% experienced hospitalization. Comorbidities in this population were minor, with a mean Charlson Comorbidity Index score calculated as 0.12. Table 2 summarizes the antidepressant use patterns and antidepressant therapy persistence during pregnancy. Nearly 80% of pregnant women were prescribed selective serotonin reuptake inhibitors, and 20% used more than 1 antidepressant during the antenatal period. Less than 40% initiated antidepressant treatment during the first trimester. Nearly 45% of the women showed treatment nonpersistence to antidepressant medication therapy with a gap ≥ 15 days between 2 consecutive prescriptions before 180 days or maternal delivery. The estimated median time to discontinuation of antidepressant use during pregnancy was 80 days (Figure 2) . Table 3 shows the associations between potential predictors and risk for antidepressant treatment nonpersistence during pregnancy. Race, a history of antidepressant use before pregnancy, hospitalization, and total number of physician office visits during the 1 year before becoming pregnant were assciated with nonpersistence with antidepressants in pregnant women. The risk for antidepressant nonpersistence during pregnancy increased by 36% in nonwhite women (vs. whites) and by 44% in women who used antidepressants during the 1 year before becoming pregnant.
■■ Discussion
Although psychological treatments with proven efficacy are available for the management of depression, antidepressant pharmacotherapy is the most common form of treatment. 33, 34 Women with 4 or more prior depressive episodes or a depressive episode 6 months before pregnancy or women of black race or Hispanic ethnicity are at higher risk for depression relapse and potentially have poor outcomes associated with a major depressive episode.
14 Moreover, women from low socioeconomic backgrounds may have a higher risk for associated social risk factors, for instance, limited social support, exposure to domestic violence, or single parenthood, that add complicating factors when determining a treatment plan or may add to the risk for major depressive symptoms. 35 Antidepressant pharmacotherapy poses risks in pregnancy. The risks to the fetus, neonate, and mother must be weighed against the benefits to maternal well-being and effect of antenatal depression on obstetrical outcomes and increased risk for postpartum depression. 36 Some research shows evidence that discontinuation of antidepressant treatment during pregnancy is associated with relapse of major depression. 22, 37 Thus, gaining a better understanding of the magnitude and predictors of Women who initiated antidepressant treatment and filled at least 2 antidepressant prescriptions during pregnancy (N = 804)
FIGURE 1
Patient Selection 98.5 (792) 3-4, % (n) 0.9 (7) ≥ 5, % (n) 0.6 (5) Antidepressant use during 1 year before pregnancy, % (n) 38.6 (310) History of depression during 1 year before pregnancy, % (n) 17.9 (144) SD = standard deviation.
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Characteristics of a Cohort of LowIncome, Insured Pregnant Women Diagnosed with Depression
antidepressant nonpersistence may provide additional insights for effectively managing depression in low-income pregnant women. To our knowledge, this research is one of the first explorations examining the association between patient predisposing characteristics and antidepressant use behavior in low-income pregnant women.
We found actual antidepressant treatment persistence during pregnancy was poor and similar to the general overall nonpregnant male/female population, where 40%-50% of patients discontinue antidepressant therapy within 6 months. [26] [27] [28] 38 For instance, in the United Kingdom and Spain, 40% and 56% of patients abandon antidepressant treatment during the first 3 and 4 months after initiating the treatment. 27, 39 A U.S. study of a large sample of health maintenance organization patients found that 32%-42% had not filled antidepressant medication prescriptions 6-8 weeks after starting treatment. 38 Although improving antidepressant treatment persistence and outcomes are important goals across various adult populations, pregnancy adds special circumstances that may require additional individualized attention. We cannot rule out the possibility of adverse effects on maternal and newborn outcomes as a contributing factor leading to the discontinuation of antidepressant therapy during pregnancy. Some women may switch to psychological or other alternative therapy after discontinuing pharmacological treatment in an effort to continue some form of antidepressant therapy while avoiding untoward effects on the fetus. Further studies examining clinical outcomes and persistence are needed to understand antenatal antidepressant medication use behavior. Research identifying differences between pregnant versus nonpregnant women's access to and persistence with antidepressant medications is needed.
Our study found that less than 40% of pregnant women initiated antidepressant therapy during the first trimester. However, this does not mean overall antenatal antidepressant use decreased during pregnancy. Notably, nearly half of our study cohort initiated therapy during the second trimester. Possibly, women engage in evaluating the risks and benefits of treatment versus nontreatment for depression and weigh the pros and cons of initiating antidepressant medication use during pregnancy. Risk benefit conversations with clinicians may play an important role in medical prescriber decision making.
For the predictors of treatment nonpersistence, we observed lower persistence among nonwhite women, as well as those with a history of depression during 1 year before pregnancy. Our analysis showed racial disparities for antidepressant medication use as defined by persistence among white and nonwhite races. The inadequate antidepressant medication treatment levels among all pregnant women in our study, as well as the racial disparities in medication use patterns when viewed in context with overall depression prevalence in minority populations, suggest areas of concern needing future research. Racial differences about treatment preferences for depression and collateral health beliefs may influence medication use behavior during pregnancy. Women with a history of antidepressant use before pregnancy were also less likely to persist in antidepressant use, suggesting that past antidepressant use behavior may impact antidepressant medication use during pregnancy. When a pregnant woman shows recurrent or severe depression, pharmacological therapy is usually recommended. To address all the challenges associated with antidepressant pharmacotherapy use during the gestational period, additional research is needed to develop optimal medication treatment guidelines for pregnant women experiencing severe or recurrent depression. 
Time to Discontinuation of Antidepressant Therapy During Pregnancy
Limitations
This study represents a preliminary exploration of antidepressant medication use behavior in women during pregnancy. The results should be interpreted in light of some limitations. We did not assess alternative antidepression therapy use. Our 280-day gestation from date of maternal delivery assumes full-term births and may affect our estimates for the antenatal period and time frame for trimesters. The measure for persistence depends on pharmacy claims data that do not necessarily reflect actual antidepressant medication use in pregnant women. We also assumed that a prescription filled was a prescription taken. Antidepressant therapy may have been discontinued by the prescriber for clinically appropriate reasons, such as potential adverse effects on maternal or newborn outcomes, lack of efficacy, or conversion to nonpharmacological treatments. The severity of each patient's depressive conditions could not be obtained from claims data, thus medication use behavior cannot be linked to clinical outcomes. In addition, we found 40% of the women used antidepressants in the year prior to pregnancy, but less than 20% had a diagnosis of depression. One possible reason for this finding may be because we identified our cohort with major depression by using the primary diagnoses and did not include secondary or tertiary diagnoses. This absence may have prevented us from capturing all the diagnoses for depression. Moreover, we did not identify off-label indications for antidepressant medication use. Finally, the study cohort consisted of pregnant women enrolled in South Carolina Medicaid, predominantly with moderate to low incomes. Although this population may represent many low income and insured women in the United States, different results may be found for other states or in a more affluent cohort.
■■ Conclusions
Despite limitations, our findings suggest implications deserving further investigation for clinicians and other policymakers responsible for appropriate antidepressant medication use in pregnant women. Our study suggests that antidepressant medication persistence is as poor as that found in other populations and that racial disparities exist in low-income pregnant women. Previous research shows medication adherence as being associated with lower medical costs. 25, 31, 40 Thus, further studies are needed to assess the relationship between antidepressant medication persistence and health care utilization and costs in pregnant women. Such studies would provide evidence for policymakers and health care providers to optimize mental health benefits for pregnant women and further the development of effective interventions to achieve improved treatment outcomes and cost savings. Additional research is needed in larger populations, particularly with appropriate adherenceenhancing interventions, to fully explore associations between antidepressant pharmacotherapy persistence during pregnancy and the benefits and risks related to maternal and newborn outcomes. Selectively targeting high-risk pregnant women with depression, using known predisposing characteristics and a review of the woman's past medication use behaviors as a guide, may serve to identify women more prone to antidepressant medication treatment nonpersistence for gestational depression. Having a strategy to identify those at risk for subpar antidepressant medication use may help clinicians more effectively manage depression in low-income, insured pregnant women in practice settings. 
